Skip to main content
Top
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | Esophagitis | Research

Risk factors for esophageal squamous cell carcinoma and its histological precursor lesions in China: a multicenter cross-sectional study

Authors: Chen Niu, Yong Liu, Jialin Wang, Yuqin Liu, Shaokai Zhang, Yongzhen Zhang, Liwei Zhang, Deli Zhao, Fugang Liu, Lina Chao, Xinzheng Wang, Chunli Zhang, Guohui Song, Zhiyi Zhang, Youpeng Li, Zheng Yan, Yongxiu Wen, Yinyin Ge, Zhaoping Zang, Wei Feng, Haiping Zhang, Lixin Tao, Rena Nakyeyune, Yi Shen, Yi Shao, Xiuhua Guo, Toni Miles, Aiming Yang, Fen Liu, Guiqi Wang

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

Despite research efforts, the causative factors that contribute to esophageal squamous cell carcinoma (ESCC) in high-risk areas have not yet been understood. In this study, we, therefore, aimed to describe the risk factors associated with ESCC and its precursor lesions.

Methods

We performed an endoscopic examination of 44,857 individuals aged 40–69 years from five high incidence regions of China in 2017–2018. Participants were classified as 4 groups of normal control, esophagitis, low-grade intraepithelial neoplasia (LGIN) and high-grade intraepithelial neoplasia/esophageal squamous cell carcinoma (HGIN/ESCC) using an unconditional logistic regression determine risk factors.

Results

We identified 4890 esophagitis, 1874 LGIN and 437 HGIN/ESCC cases. Crude odds ratios (ORs) and adjusted odds ratios were calculated using unconditional logistic regression. Drinking well and surface water, salty diet, and positive family history of cancer were the common risk factors for esophagitis, LGIN and HGIN/ESCC. History of chronic hepatitis/cirrhosis was the greatest risk factor of esophagitis (adjusted OR 2.96, 95%CI 2.52–3.47) and HGIN/ESCC (adjusted OR 1.91, 95%CI 1.03–3.22). Pesticide exposure (adjusted OR 1.20, 95%CI 1.05–1.37) was essential risk factor of LGIN.

Conclusions

Among individuals aged 40–69 years in high incidence regions of upper gastrointestinal cancer, the results provided important epidemiological evidence for the prevention of different precancerous lesions of ESCC.
Appendix
Available only for authorised users
Literature
2.
go back to reference Zheng RS, Sun KX, Zhang SW, Zeng HM, Zou XN, Chen R, et al. Report of cancer epidemiology in China, 2015. Zhonghua Zhong Liu Za Zhi. 2019;41(1):19–28.PubMed Zheng RS, Sun KX, Zhang SW, Zeng HM, Zou XN, Chen R, et al. Report of cancer epidemiology in China, 2015. Zhonghua Zhong Liu Za Zhi. 2019;41(1):19–28.PubMed
5.
go back to reference Blot WJ, Li JY. Some considerations in the design of a nutrition intervention trial in Linxian, People’s Republic of China. Natl Cancer Inst Monogr. 1985;69:29–34.PubMed Blot WJ, Li JY. Some considerations in the design of a nutrition intervention trial in Linxian, People’s Republic of China. Natl Cancer Inst Monogr. 1985;69:29–34.PubMed
7.
go back to reference Hamilton S. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2000. Hamilton S. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2000.
16.
go back to reference Pan D, Su M, Zhang T, Miao C, Fu L, Yang L, et al. A distinct epidemiologic pattern of precancerous lesions of esophageal squamous cell carcinoma in a high-risk area of Huai’an, Jiangsu Province, China. Cancer Prev Res (Phila). 2019;12(7):449–62.CrossRef Pan D, Su M, Zhang T, Miao C, Fu L, Yang L, et al. A distinct epidemiologic pattern of precancerous lesions of esophageal squamous cell carcinoma in a high-risk area of Huai’an, Jiangsu Province, China. Cancer Prev Res (Phila). 2019;12(7):449–62.CrossRef
17.
go back to reference Dong Z. Guidelines for cancer screening and early diagnosis and treatment in China. Beijing: Peking University Medical Press; 2005. Dong Z. Guidelines for cancer screening and early diagnosis and treatment in China. Beijing: Peking University Medical Press; 2005.
23.
go back to reference Han JY, Xu ZX, Xing HP. A historical cohort study on the effect of drinking water improvement to the mortality of esophageal carcinoma among Linzhou residents. Zhonghua Liu Xing Bing Xue Za Zhi. 2007;28(5):515–6.PubMed Han JY, Xu ZX, Xing HP. A historical cohort study on the effect of drinking water improvement to the mortality of esophageal carcinoma among Linzhou residents. Zhonghua Liu Xing Bing Xue Za Zhi. 2007;28(5):515–6.PubMed
26.
go back to reference Abnet CC, Corley DA, Freedman ND, Kamangar F. Diet and upper gastrointestinal malignancies. Gastroenterology. 2015;148(6):1234–1243.e1234.CrossRef Abnet CC, Corley DA, Freedman ND, Kamangar F. Diet and upper gastrointestinal malignancies. Gastroenterology. 2015;148(6):1234–1243.e1234.CrossRef
27.
go back to reference Fox JG, Dangler CA, Taylor NS, King A, Koh TJ, Wang TC. High-salt diet induces gastric epithelial hyperplasia and parietal cell loss, and enhances helicobacter pylori colonization in C57BL/6 mice. Cancer Res. 1999;59(19):4823–8.PubMed Fox JG, Dangler CA, Taylor NS, King A, Koh TJ, Wang TC. High-salt diet induces gastric epithelial hyperplasia and parietal cell loss, and enhances helicobacter pylori colonization in C57BL/6 mice. Cancer Res. 1999;59(19):4823–8.PubMed
Metadata
Title
Risk factors for esophageal squamous cell carcinoma and its histological precursor lesions in China: a multicenter cross-sectional study
Authors
Chen Niu
Yong Liu
Jialin Wang
Yuqin Liu
Shaokai Zhang
Yongzhen Zhang
Liwei Zhang
Deli Zhao
Fugang Liu
Lina Chao
Xinzheng Wang
Chunli Zhang
Guohui Song
Zhiyi Zhang
Youpeng Li
Zheng Yan
Yongxiu Wen
Yinyin Ge
Zhaoping Zang
Wei Feng
Haiping Zhang
Lixin Tao
Rena Nakyeyune
Yi Shen
Yi Shao
Xiuhua Guo
Toni Miles
Aiming Yang
Fen Liu
Guiqi Wang
Publication date
01-12-2021
Publisher
BioMed Central
Keyword
Esophagitis
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-08764-x

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine